Systemic sclerosis & Raynaud's
CD19-targeting chimeric antigen receptor (CAR) T-cell therapy in patients with diffuse systemic sclerosis: a case series
Authors' conclusion
We provide the first evidence that CD19-targeting CAR T-cell therapy might intercept with the progression of fibrotic organ manifestations in patients with systemic sclerosis.
Study context
- Population
- Patients with severe diffuse SSc with an insufficient response to at least two treatments, University Hospital Erlangen, Germany (median age 42 years [IQR 36–53]; four men and two women; all White European)median follow-up 487 days
- Participants
- 6 patients
- Outcome
- Events:
- Event-free time
- Treatment intensification
- Follow-up
- Within the observational period (median 487 days, IQR 342-585)
Methodological detailssingle-centre, consecutively recruited
- Single-centre
- Consecutively recruited
Main finding
As reported in the abstract
- No events occurred within the observational period
Observational data: associations, not effects.
Secondary outcomes
Probability of improvement in modified American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) score · 6 months
- Probability of improvement in the ACR-CRISS score increased to a median of 100% (IQR 100-100)
Modified Rodnan Skin Score (mRSS) decrease · within 100 days
- Median mRSS decrease, % (IQR 29-38)
- 31%
- Median mRSS decrease, points (IQR 7-13)
- 8
Extent of disease on CT scan
- Median decrease (IQR 3-4), due to reduction of ground-glass opacities; reticular pattern remained stable
- 4%
FVC improvement · latest observational timepoint
- Median FVC improvement (IQR 18-275)
- 195 mL
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →